Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Dezember 2025 02:00 ET | Quelle: Scancell Holdings Plc

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and...
07. November 2025 02:12 ET | Quelle: Scancell Holdings Plc

Research Update

Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark in...
11. September 2025 02:00 ET | Quelle: Scancell Holdings Plc

Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a...
22. Juli 2025 02:00 ET | Quelle: Scancell Holdings Plc

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type...